Evidence map›Paper›PMID 29170905›Full record

ReviewEndocrine2018

Irisin in metabolic diseases.

Stergios A Polyzos, Athanasios D Anastasilakis, Zoe A Efstathiadou, Polyzois Makras, Nikolaos Perakakis, Jannis Kountouras, Christos S Mantzoros

Abstract readReview
PubMed Publisher
In one paragraph

Review in Endocrine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed, 3 pooled it
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 3 syntheses or guidelines pooled it, 254 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Stergios A PolyzosFirst Department of Pharmacology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece. stergios@endo.gr.
Athanasios D AnastasilakisDepartment of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece.
Zoe A EfstathiadouDepartment of Endocrinology, Ippokration General Hospital, Thessaloniki, Greece.
Polyzois MakrasDepartment of Endocrinology and Diabetes, 251 Hellenic Air Force General Hospital, Athens, Greece.
Nikolaos PerakakisDivision of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Jannis KountourasSecond Medical Clinic, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Christos S MantzorosDivision of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Aristotle University of Thessaloniki · GR424 General Military Hospital · GRBeth Israel Deaconess Medical Center · USHarvard University · USHellenic Air Force · GRIppokrateio General Hospital of Thessaloniki · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIrisin is a myokine/adipokine induced by the exercise in mice and humans, which is proposed to induce "browning" of white adipose tissue, its primary target, thus increasing thermogenesis and energy expenditure. Since its identification, irisin has been linked to favorable effects on metabolic diseases, including obesity, type 2 diabetes mellitus (T2DM), lipid metabolism and cardiovascular disease (CVD), nonalcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), and metabolic bone diseases. Generally, despite the promising profile of irisin in rodents, its effects on human are less recognized. REVIEW: Most, but not all studies show a positive association between irisin and indices of adiposity. In T2DM, NAFLD, and CVD, most observational studies reported lower irisin levels in patients than controls. Regarding metabolic bone diseases, irisin is positively associated with bone mineral density and strength in athletes, and inversely associated with osteoporotic fractures in postmenopausal osteoporosis. In PCOS, data remain largely conflicting. Irisin does not seem to be further reduced when two metabolic diseases, e.g., T2DM and NAFLD, or obesity and NAFLD exist though more data are needed. Furthermore, it seems that diverse confounders may have affected the results of different clinical studies.

conclusionIrisin remains an appealing molecule from a pathophysiological point of view and an appealing therapeutic target for metabolic diseases, albeit much research is still needed.

Indexed as

Adipose Tissue, WhiteAdiposityBone DensityFibronectinsHumansMetabolic DiseasesMuscle, SkeletalFibronectinsFNDC5 protein, ratCardiovascular diseaseDiabetesIrisinMyokineNonalcoholic fatty liver diseaseObesity

Identifiers

PMID29170905
OpenAlexW2768402021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.